Granulocyte-colony stimulating factor (G-CSF)

Granulocyte-colony stimulating factor (G-CSF) is a naturally occurring cytokine and glycoprotein that stimulates the proliferation, differentiation, and functional activation of neutrophil precursors in the bone marrow, resulting in increased production and mobilization of neutrophils into the bloodstream[1][2]. G-CSF is primarily produced by fibroblasts, endothelial cells, and immunocompetent cells such as monocytes and macrophages in response to inflammatory signals[1][2]. Its receptor (G-CSFR) is part of the cytokine and hematopoietin receptor superfamily and mediates signal transduction primarily through JAK/STAT and MAPK pathways[1][2]. Pharmacologically, recombinant forms of G-CSF (such as filgrastim, lenograstim, and pegfilgrastim) are widely used to prevent or treat neutropenia (most often secondary to chemotherapy), as well as to mobilize hematopoietic stem cells ahead of transplantation[5][6][7]. In addition to its primary role in hematopoiesis, G-CSF exhibits broader biological activities, including effects on endothelial cells, osteoclast activation, and emerging neuroprotective functions[1][2]. Key clinical considerations include efficacy in neutropenia management, stem cell mobilization, common adverse effects such as bone pain, and rare but serious risks such as splenic rupture or leukemic transformation in individuals with predisposing mutations[5][7].

Other names

Colony-stimulating factor 3CSF-3GCSF

Agonist of G-CSF receptor (G-CSFR), stimulating proliferation and differentiation of myeloid precursors to neutrophils; Mobilization of hematopoietic stem cells from bone marrow to peripheral blood; Modulation of immune cell function and survival